New drug combo for myeloid blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug (ICP-248) combined with standard treatment azacitidine for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). It aims to find out if the combo is safe and effective for those who haven't been helped by other treatments or cannot have strong chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a confirmed diagnosis of AML (except a specific type called APL) or MDS.
- For AML: You either have not responded to or relapsed after previous treatment, or you are newly diagnosed and age 60 or older (or age 18-59 with health issues making strong chemo unsafe).
- For MDS: You score higher than 3 on a standard risk scale and more than 5% of your bone marrow cells are blasts (immature cells).
- Your doctor expects you to live at least 12 more weeks.
- Your kidneys and liver work well enough (creatinine clearance at least 30 mL/min and normal liver tests).
- You have not had azacitidine or a similar drug (BCL-2 inhibitor) without improvement or with side effects.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two combinations of chemotherapy drugs to see which one works better for people with certain types of acute myeloid leukemia (AML) or a high-risk bone marrow disorder called MDS. The goal is to find a treatment that may help control the disease and improve quality of life.
This trial tests a new drug (CLN-049) combined with two standard AML medicines (azacitidine and venetoclax) for people who are newly diagnosed with AML and cannot have intensive chemotherapy. It aims to see if this combination is safe and effective for those who are not fit for the usual strong treatment.
This trial tests a new drug combination (iadademstat plus azacitidine and venetoclax) for people with newly diagnosed AML who cannot have or do not want standard intensive chemotherapy. The goal is to see if adding iadademstat makes the treatment work better.
This trial tests a new drug called LP-108 combined with azacitidine for people with certain blood cancers like acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or chronic myelomonocytic leukemia (CMML). It aims to see if the combination is safe and helps shrink or control the cancer.
This trial tests a new drug called APG1252 combined with azacitidine (AZA) for people with high-risk AML or certain related blood cancers. The goal is to see if the combination works better than standard treatments.
This trial tests a new drug, MAX-40279, combined with two standard treatments (venetoclax and azacitidine) for people with newly diagnosed acute myeloid leukemia who are not healthy enough for intensive chemotherapy. The goal is to see if adding this drug improves outcomes.
Hear when a new Acute Myelogenous Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.